Loading…
Growing Opportunities in Outsourced Biopharma APIs
[...]the increase in the percentage of outsourced biologies points to the fact that contract manufacturing of biologies today is a strategic, integral part of the industry. Since BioPlan Associates began evaluating outsourced production in 2010, there has been a steady increase. [...]outsourcing has...
Saved in:
Published in: | Pharmaceutical Technology 2023-10, Vol.47 (10), p.48-49 |
---|---|
Main Author: | |
Format: | Magazinearticle |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | [...]the increase in the percentage of outsourced biologies points to the fact that contract manufacturing of biologies today is a strategic, integral part of the industry. Since BioPlan Associates began evaluating outsourced production in 2010, there has been a steady increase. [...]outsourcing has become an attractive option for its cost-effectiveness, allowing companies to mitigate risks and operational expenses. [...]there is a strategic move toward focusing on core activities such as R&D, with companies offloading the manufacturing aspect to specialized contract organizations. |
---|---|
ISSN: | 1543-2521 2150-7376 |